Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ:MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the Class Period from October 10, 2025, to November 12, 2025 [7]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [7]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [7]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [7]. Stock Performance - Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share prior to November 12, 2025, despite no fundamental news justifying such a rise [7]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [7]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [7].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the period from October 10, 2025, to November 12, 2025 [7]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [7]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [7]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [7]. Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [7]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [7]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [7].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Picard Medical, Inc. (PMI) securities between September 2, 2025, and October 31, 2025, due to allegations of a fraudulent stock promotion scheme [1][2]. Group 1: Allegations Against Picard Medical - The complaint alleges that Picard Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [2]. - It is claimed that insiders and/or affiliates utilized offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures reportedly failed to mention the false rumors and artificial trading activity that influenced the stock price [2]. Group 2: Stock Price Impact - On October 24, 2025, Picard's stock price experienced a significant crash of 70%, dropping to $3.99 per share, and has since continued to decline to approximately $2.00 per share [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by April 3, 2026, although participation is not required to be eligible for recovery [4]. - Individuals can choose to remain absent class members if they do not wish to take action [4]. Group 4: Robbins LLP Overview - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the period from October 10, 2025, to November 12, 2025 [8]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [8]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [8]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [8]. Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [8]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [8]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [8].